Search

Your search keyword '"Thierry Berghmans"' showing total 251 results

Search Constraints

Start Over You searched for: Author "Thierry Berghmans" Remove constraint Author: "Thierry Berghmans"
251 results on '"Thierry Berghmans"'

Search Results

1. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition

2. What Does N2 Lymph Node Involvement Mean for Patients with Non-Small Cell Lung Cancer (NSCLC)?—A Review of Implications for Diagnosis and Treatment

3. 607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study

4. Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review

6. Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries

7. Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy

8. Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

9. Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept

10. Advances in target therapy in lung cancer

11. A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer

12. Updates in oncology

13. Are intensive cares worthwhile for breast cancer patients: the experience of an oncological ICU.

14. The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses

15. Continuous renal replacement therapy for acute renal failure in patients with cancer: a well-tolerated adjunct treatment

16. VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study

17. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables

18. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer

19. European Respiratory Society guideline on various aspects of quality in lung cancer care

21. Management of thymoma associated autoimmune pure red cell aplasia: Case report and systematic review of the literature

22. Author response for 'Preclinical evaluation of <scp>CDK4</scp> phosphorylation predicts high sensitivity of pleural mesotheliomas to <scp>CDK4</scp> /6 inhibition'

23. Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey

24. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition

25. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition

26. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib

27. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

28. Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion

30. Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies

31. Lung Cancer in Belgium

32. Oligometastatic non-small cell lung cancer: from biology to clinical practice

33. Dépistage du cancer bronchique par tomodensitométrie à faible dose :une revue systématique des essais contrôlés randomisés

34. Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?

35. Cancer bronchique : le pronostic en soins intensifs dépendrait surtout de la complication

36. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report

37. Cryobiopsy and dye marking guided by electromagnetic navigation bronchoscopy before resection of pulmonary nodule

38. Quel rôle pour l’irradiation cérébrale prophylactique dans le cancer à petites cellules ?Une étude rétrospective unicentrique

39. Les traitements périopératoires des cancers bronchiques non à petites cellules :quelles options en 2020 ?

40. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

41. Current and future research efforts in oligometastatic non-small cell lung cancer-a systematic review

42. Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

43. Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept

44. Current challenges in the management of nonsmall cell lung cancer brain metastases

45. Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm

46. La classification TNM en pratique

47. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC) : lung cancer

48. Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review

49. New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey

50. Les inhibiteurs des freins immunitaires (anticorps anti-PD1 et anti-PD-L1), une nouvelle arme thérapeutique dans les cancers bronchiques non à petites cellules

Catalog

Books, media, physical & digital resources